Liquidia’s PRINT-enabled YUTREPIA launch is scaling like a potential blockbuster—yet the stock remains a “dominant challenger” with binary patent risk.
Overview
Liquidia is a commercial-stage biopharma that has rapidly transitioned from an R&D platform company to a scaling pharmaceutical business anchored by its proprietary PRINT particle-engineering technology. The key catalyst is YUTREPIA (treprostinil) inhalation powder, which received full FDA approval on May 23, 2025 for PAH and PH-ILD and launched commercially in June 2025. Adoption was unusually fast: 2025 net product sales reached $148.3M, with Q4 sales of $90.1M (+74% sequential), supporting a swift inflection to quarterly profitability and culminating in Q4 net income of $14.6M. Liquidia also earns service revenue via a Sandoz promotion/profit-share arrangement for generic treprostinil injection, though this stream declined to $10.0M in 2025. By early 2026, the company reported >3,600 unique prescriptions and ~2,900 patients treated, indicating meaningful penetration. Liquidity is solid with $190.7M cash at year-end 2025, supplemented by a HealthCare Royalty facility. The opportunity centers on continued YUTREPIA ramp (especially PH-ILD) and potential L606 launch, while the principal risk is binary patent litigation with United Therapeutics that could threaten YUTREPIA’s market access.